“US Breast Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Breast Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Breast Cancer drug market based upon development process. For Report Sample Contact: rajesh@pnspharma.com

1. US Breast Cancer Drug Pipeline Analysis
The pharmaceutical companies have recently been focusing increasingly on women's health.
Among the diseases specific to women, breast cancer has become one of the leading causes of
death for the women population globally and accounts for almost 3 per cent of the causes of
death in women. It has been estimated that one in every 12 women is most likely to develop
breast cancer at some point in her life, owing to risk factors such as hormonal effects, age
and genetic predisposition. According to the American Cancer Society (ACS), the cases of
women with breast cancer accounts to more than 1 in 4 cancer patients in the US. It is further
estimated that in 2013, close to 32,000 new cases of breast cancer are expected to be
diagnosed and close to 40,000 people are expected to die from breast cancer. By 2020, the
combined sales of emerging and new therapies would account for more than 25% of the
overall market for breast cancer drug treatments.
“US Breast Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the
various drugs being developed for the treatment of Breast Cancer. Research report covers all
the ongoing drugs being developed in various clinical development phases. This report enables
pharmaceutical companies, collaborators and other associated stake holders to identify and
analyze the available investment opportunity in the Breast Cancer drug market based upon
development process.
For Report Sample Contact: rajesh@pnspharma.com
Following parameters for each drug profile in development phase are covered in “US Breast
Cancer Drug Pipeline Analysis” research report:
• Drug Profile Overview
• Alternate Names for Drug
• Active Indication
• Phase of Development
• Mechanism of Action
• Brand Name
• Patent Information
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator

2. • Administrative Route
• Drug Class
• ATC Codes
US Breast Cancer Drug Pipeline by Clinical Phase:
• Research: 9
• Preclinical: 43
• Phase-I: 33
• Phase-I/II: 19
• Phase-II: 73
• Phase-II/III: 2
• Phase-III: 12
• Registered: 3
• Marketed: 28
For Report Sample Contact: rajesh@pnspharma.com
Each Drug Profile has Tables Representing Following Information:
• Alternate Names
• Originator & Owner
• Collaborator
• Technology Provider
• Licensee
• Highest Development Phase
• Indications
• Class
• Mechanism of Action
• ATC Code
• Designated Brand Name